Literature DB >> 28111137

The regulatory role of long noncoding RNAs in cancer.

Ying Tang1, Belamy B Cheung2, Bernard Atmadibrata2, Glenn M Marshall2, Marcel E Dinger3, Pei Y Liu4, Tao Liu5.   

Abstract

With the advances in genomic analysis technologies, especially next-generation RNA sequencing, a large number of new transcripts have been discovered, leading to better understanding of long noncoding RNAs (lncRNAs). Recent investigations have provided firm evidence for the critical roles of lncRNAs in chromatin modification, gene transcription, RNA splicing, RNA transport and translation. In vitro and in vivo studies have also proven that aberrant lncRNA expression is essential for the initiation and progression of cancers. Due to their unique tissue- and cancer-specific expression profiles, aberrant expression of lncRNAs can be used as reliable prognostic markers for cancer diagnoses and treatment stratification, and lncRNAs are novel therapeutic targets with high therapeutic windows.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Gene expression; Long noncoding RNA

Mesh:

Substances:

Year:  2017        PMID: 28111137     DOI: 10.1016/j.canlet.2017.01.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  49 in total

1.  The value of LncRNA SNHG5 as a marker for the diagnosis and prognosis of gastric cancer.

Authors:  Xiangying Li; Yaqing Du; Yunfang Wang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Upregulation of LncRNA BCYRN1 promotes tumor progression and enhances EpCAM expression in gastric carcinoma.

Authors:  Hao Ren; Xiaomin Yang; Yongmei Yang; Xiaoyu Zhang; Rui Zhao; Ran Wei; Xin Zhang; Yi Zhang
Journal:  Oncotarget       Date:  2017-12-21

3.  Identification of genomic expression differences between right-sided and left-sided colon cancer based on bioinformatics analysis.

Authors:  Qiliang Peng; Kaisu Lin; Tao Chang; Li Zou; Pengfei Xing; Yuntian Shen; Yaqun Zhu
Journal:  Onco Targets Ther       Date:  2018-01-31       Impact factor: 4.147

4.  LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194.

Authors:  Jihong An; Weiling Lv; Yongzhou Zhang
Journal:  Onco Targets Ther       Date:  2017-11-10       Impact factor: 4.147

5.  Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer.

Authors:  Shushan Yan; Bing Han; Shunyuan Gao; Xiaochen Wang; Zengfang Wang; Fakai Wang; Jianjun Zhang; Donghua Xu; Beicheng Sun
Journal:  Oncotarget       Date:  2017-06-16

6.  CASC15 polymorphisms are correlated with cervical cancer susceptibility in Chinese women.

Authors:  Ziying Gao; Zichao Xiong; Yao Sun; Jiamin Wu; Jianfeng Liu; Yuanwei Liu; Haiyue Li; Bin Li; Tianbo Jin
Journal:  Mol Genet Genomic Med       Date:  2020-04-23       Impact factor: 2.183

7.  SP1-Induced Upregulation of lncRNA LINC00514 Promotes Tumor Proliferation and Metastasis in Osteosarcoma by Regulating miR-708.

Authors:  Li-Dong Mi; Chuan-Xiu Sun; Sheng-Wei He; Guang-Yu Du
Journal:  Cancer Manag Res       Date:  2020-05-11       Impact factor: 3.989

8.  Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA.

Authors:  Yonghao Zhan; Zhicong Chen; Yifan Li; Anbang He; Shiming He; Yanqing Gong; Xuesong Li; Liqun Zhou
Journal:  J Exp Clin Cancer Res       Date:  2018-11-12

9.  LINC00671 suppresses cell proliferation and metastasis in pancreatic cancer by inhibiting AKT and ERK signaling pathway.

Authors:  Shibin Qu; Kunwei Niu; Jianlin Wang; Jimin Dai; Anutosh Ganguly; Chao Gao; Yuzi Tian; Zhibin Lin; Xisheng Yang; Xuan Zhang; Zhengcai Liu; Haimin Li
Journal:  Cancer Gene Ther       Date:  2020-08-15       Impact factor: 5.987

10.  Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer.

Authors:  Marianna Buttarelli; Marta De Donato; Giuseppina Raspaglio; Gabriele Babini; Alessandra Ciucci; Enrica Martinelli; Pina Baccaro; Tina Pasciuto; Anna Fagotti; Giovanni Scambia; Daniela Gallo
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.